NASDAQ:YARW

Yarrow Bioscience Q4 2024 Earnings Results & Report

Yarrow Bioscience logo
$14.35 +0.00 (+0.03%)
As of 11:12 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Yarrow Bioscience beat analyst earnings expectations but missed on revenue in its Q4 2024 results, released March 6, 2025. The company reported EPS of -$14.00 versus the -$15.50 consensus estimate, while revenue of $84 thousand fell short of the $140 thousand estimate by $56.00 thousand.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Yarrow Bioscience EPS Results

Actual EPS
-$14.00
Consensus EPS
-$15.50
Beat/Miss
Beat by +$1.50
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Yarrow Bioscience Revenue Results

Actual Revenue
$84 thousand
Expected Revenue
$140 thousand
Beat/Miss
Missed by -$56.00 thousand
YoY Revenue Growth
N/A

Yarrow Bioscience Q4 2024 Earnings FAQ

Yarrow Bioscience (NASDAQ:YARW) reported earnings of -$14.00 per share for Q4 2024, beating the consensus estimate of -$15.50. The report was announced on Thursday, March 6, 2025.

Yarrow Bioscience reported revenue of $84 thousand for Q4 2024, against a consensus estimate of $140 thousand.

Yarrow Bioscience Earnings Headlines

Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
See More Yarrow Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Yarrow Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Yarrow Bioscience and other key companies, straight to your email.

About Yarrow Bioscience

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

View Yarrow Bioscience Profile